MDT

88.67

+2.37%↑

A

116.74

+2.75%↑

VEEV

166.74

-2.86%↓

HQY

81.7

+1%↑

TLRY

6.73

+4.5%↑

MDT

88.67

+2.37%↑

A

116.74

+2.75%↑

VEEV

166.74

-2.86%↓

HQY

81.7

+1%↑

TLRY

6.73

+4.5%↑

MDT

88.67

+2.37%↑

A

116.74

+2.75%↑

VEEV

166.74

-2.86%↓

HQY

81.7

+1%↑

TLRY

6.73

+4.5%↑

MDT

88.67

+2.37%↑

A

116.74

+2.75%↑

VEEV

166.74

-2.86%↓

HQY

81.7

+1%↑

TLRY

6.73

+4.5%↑

MDT

88.67

+2.37%↑

A

116.74

+2.75%↑

VEEV

166.74

-2.86%↓

HQY

81.7

+1%↑

TLRY

6.73

+4.5%↑

Search

United Therapeutics Corp

Avatud

SektorTervishoid

581.39 3.02

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

558.82

Max

585.67

Põhinäitajad

By Trading Economics

Sissetulek

26M

364M

Müük

-9.3M

790M

P/E

Sektori keskmine

20.102

66.418

Kasumimarginaal

46.102

Töötajad

1,400

EBITDA

61M

524M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.7% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. apr 2026

Turustatistika

By TradingEconomics

Turukapital

3.1B

25B

Eelmine avamishind

578.37

Eelmine sulgemishind

581.39

Uudiste sentiment

By Acuity

50%

50%

151 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

United Therapeutics Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2026, 17:26 UTC

Uudisväärsed sündmused

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. apr 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. apr 2026, 23:47 UTC

Market Talk
Uudisväärsed sündmused

Market Talk Roundup: Latest on U.S. Politics

7. apr 2026, 23:47 UTC

Market Talk
Uudisväärsed sündmused

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. apr 2026, 23:44 UTC

Market Talk
Uudisväärsed sündmused

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:37 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:15 UTC

Market Talk
Uudisväärsed sündmused

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. apr 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. apr 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. apr 2026, 23:01 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. apr 2026, 22:58 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. apr 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

7. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. apr 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. apr 2026, 19:17 UTC

Uudisväärsed sündmused

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. apr 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. apr 2026, 18:41 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. apr 2026, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. apr 2026, 18:39 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. apr 2026, 18:24 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. apr 2026, 16:21 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

United Therapeutics Corp Prognoos

Hinnasiht

By TipRanks

10.7% tõus

12 kuu keskmine prognoos

Keskmine 626.25 USD  10.7%

Kõrge 705 USD

Madal 471 USD

Põhineb 13 Wall Streeti analüütiku instrumendi United Therapeutics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

9

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

292.345 / 309.245Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

151 / 349 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat